Europe Glycomics Market

The Europe glycomics market is expected to grow from US$ 428.99 million in 2022 to US$ 899.30 million by 2028; it is estimated to grow at a CAGR of 13.1% from 2022 to 2028.

 Glycomics is the study of glycans or sugar structures found in the human body. These glycans, which may be exceedingly complex, are found in many microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on advancing technologies that can offer better alternatives to conventional techniques. For instance, in June 2018, the LCMS-9030 Quadrupole Time of Flight (Q-TOF) mass spectrometry (MS) system with informatics support—powered by PREMIER Biosoft's software solutions for lipidomics and glycomics data analysis—was introduced by Shimadzu and PREMIER Biosoft, which provides bioinformatics solutions to life sciences laboratories. Shimadzu and PREMIER Biosoft have partnered with an objective to improve lipidomics and glycomics research. Further, in June 2022, Thermo Fisher Scientific Inc. and TransMIT GmbH Center for Mass Spectrometric Developments established a co-marketing partnership to promote the use of mass spectrometry imaging (MSI) technology for spatial multi-omics applications in pharma and clinical laboratories. This instrument can be used for omics applications, such as pharmaco-kinetic research in various tissues, metabolomics, lipidomics, proteomics, and glycomics. These advancements are propelling the glycomics market significantly.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe glycomics market. The Europe glycomics market is expected to grow at a good CAGR during the forecast period. 

 Europe Glycomics Market Revenue and Forecast to 2028 (US$ Million)  

Europe Glycomics Market Segmentation         

The Europe glycomics market is segmented based on product, application, end user, and country. Based on product, the Europe glycomics market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment dominated the market in 2022. The enzymes segment is further segmented into glycosidases, glycosyl transferases, sialyltransferases, neuraminidases, and others. The instruments segment is also segmented into mass spectrometers, MALDI-TOF, HPLC, lectin arrays, antibody arrays, and others. Similarly, the kits segment is segmented into glycan release kits, glycan labeling kits, glycan purification kits, and others. Furthermore, the reagents segment is segmented into oligosaccharides, monosaccharides, glycoproteins, and others. Based on application, the Europe glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. The drug discovery and development segment dominated the market in 2022. Based on end user, the Europe glycomics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment dominated the market in 2022. Based on country, the Europe glycomics market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.

Agilent Technologies, Inc.; Asparia Glycomics; Bruker Corporation; MERCK KGaA; New England Biolabs; S-BIO (Sumitomo Bakelite Co., Ltd.); Shimadzu Corporation; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and Waters Corporation are among the leading companies in the Europe glycomics market.     

Europe Glycomics Market Strategic Insights

Europe Glycomics Market Segmentation Analysis

Europe Glycomics Market Report Highlights

Europe Glycomics Report Scope

Europe Glycomics Market Country and Regional Insights